Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Safety and efficacy of venetoclax-based regimens for AML

Andrius Žučenka, PhD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, outlines the safety and efficacy of venetoclax-based regimens for acute myeloid leukemia (AML). Specifically, Dr Žučenka talks on special considerations that ought to be made when using the drug. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.